Compare · SENS vs SYK
SENS vs SYK
Side-by-side comparison of Senseonics Holdings Inc. (SENS) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SENS and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $112.48B, about 105.5x SENS ($1.07B).
- SYK has been more active in the news (8 items in the past 4 weeks vs 5 for SENS).
- SYK has more recent analyst coverage (25 ratings vs 8 for SENS).
- Company
- Senseonics Holdings Inc.
- Stryker Corporation
- Price
- -
- -
- Market cap
- $1.07B
- $112.48B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- AMEX
- NYSE
- IPO
- News (4w)
- 5
- 8
- Recent ratings
- 8
- 25
Senseonics Holdings Inc.
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to 90 and 180 days. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest SENS
- Barclays initiated coverage on Senseonics with a new price target
- SEC Form 4 filed by Senseonics Holdings Inc.
- SEC Form 4 filed by Senseonics Holdings Inc.
- SEC Form 4 filed by Senseonics Holdings Inc.
- SEC Form 4 filed by Senseonics Holdings Inc.
- Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas
- Senseonics To Participate in Upcoming Institutional Investor Conferences
- Director Roeder Douglas A bought $125,300 worth of shares (13,953 units at $8.98), increasing direct ownership by 9% to 171,191 units (SEC Form 4)
- SEC Form 10-Q filed by Senseonics Holdings Inc.
- Senseonics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest SYK
- Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
- Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
- Barclays initiated coverage on Stryker with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker announces leadership succession
- Stryker to announce third quarter 2026 financial results
- VP, Chief Financial Officer Wells Preston Wendell disposed of 109 shares, decreasing direct ownership by 3% to 3,661 units (SEC Form 4)
- VP, Chief Financial Officer Wells Preston Wendell disposed of 2,739 shares, decreasing direct ownership by 42% to 3,770 units (SEC Form 4)
- Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)